| abstract |
methods and systems for pharmacogenomic treatment of cardiovascular conditions. The present invention relates to systems and methods that are based on the effects of genetic variations of biological activities associated with rostafuroxin in an individual. In particular, systems, methods and compositions are described herein which are based on an identified influence on an individual rostafuroxin response of one or more polymorphisms in an intergenic or intragenic region of a gene selected from the group consisting of kcns3, thsd7a, fam46a, loc389970, hla-g, and ttc29, and / or a genetic variation in binding imbalance with it. |